calcium disodium edetate
edetate calcium disodium
(ee-de-tate kal-see-um dye-soe-dee-um) edetate-calcium-disodium,Calcium Disodium Versenate
(trade name),calcium EDTA
(trade name),calcium disodium edetate
(trade name)Classification
Therapeutic: antidotesPharmacologic: chelating agents
Indications
Action
Therapeutic effects
Pharmacokinetics
Time/action profile (urinary lead excretion)
ROUTE | ONSET | PEAK | DURATION |
IM | unknown | unknown | unknown |
IV | 1 hr | 24–48 hr | unknown |
Contraindications/Precautions
Adverse Reactions/Side Effects
Central nervous system
- headache
Ear, Eye, Nose, Throat
- lacrimation
- nasal congestion
- sneezing
Cardiovascular
- arrhythmia
- ECG changes (inverted T waves)
- hypotension
Gastrointestinal
- anorexia
- nausea
- vomiting
Genitourinary
- nephrotoxicity (most frequent)
- glycosuria
- proteinuria
Fluid and Electrolyte
- hypercalcemia
- zinc deficiency
Hematologic
- anemia
Local
- pain at IM site
- phlebitis at IV site
Musculoskeletal
- arthralgia
- myalgia
Neurologic
- numbness
- tingling
- tremor
Miscellaneous
- chills
- excessive thirst
- fever
Interactions
Drug-Drug interaction
↓ duration of action of zinc insulin preparations.Route/Dosage
Various other regimens are usedRenal Impairment
Intramuscular Intravenous (Adults) The following regimens may be repeated at monthly intervals until lead excretion is reduced toward normal.Serum creatinine 2–3 mg/dL—500 mg/m2/day for 5 days.Serum creatinine 3–4 mg/dL-500 mg/m2 every 48 hr for 3 doses.Serum creatinine > 4 mg/dL-500 mg/m2/week.Availability
Nursing implications
Nursing assessment
- Assess patient and family members for evidence of lead poisoning prior to and periodically throughout therapy. Acute lead poisoning is characterized by a metallic taste, colicky abdominal pain, vomiting, diarrhea, oliguria, and coma. Symptoms of chronic poisoning vary with severity and include anorexia, a blue-black line along the gums, intermittent vomiting, paresthesia, encephalopathy, seizures, and coma.
- Monitor intake and output and daily weight. Report discrepancies. If patient is anuric, edetate calcium disodium should be held until urine flow is established by IV hydration.
- Monitor neurologic status closely (level of consciousness, pupil response, movement). Notify health care professional immediately of any changes. Infuse slowly; rapid infusion rate may increase intracranial pressure. Restricting fluids may decrease risk of increased intracranial pressure.
- Monitor vital signs and ECG frequently. Notify health care professional of hypotension or T-wave inversion or of fever, chills, malaise, or nasal congestion. This histamine-like response usually resolves in 48 hr.
- Lab Test Considerations: Monitor serum and urine lead levels prior to and periodically during therapy. Wait at least 1 hr after infusing edetate calcium disodium before drawing serum lead level.
- Monitor urinalysis daily and serum creatinine, BUN, alkaline phosphatase, calcium, and phosphorus levels and hepatocellular enzymes. Both lead and edetate calcium disodium are nephrotoxic. Notify health care professional if hematuria, proteinuria, or large renal epithelial cells are present.
- May cause an increase in urine glucose.
Potential Nursing Diagnoses
Risk for poisoning (Indications, Patient/Family Teaching)Impaired home maintenance (Indications)
Deficient knowledge, related to medication regimen (Patient/Family Teaching)
Implementation
- Do not confuse with edetate disodium.
- Administer IM or IV; oral administration may increase absorption of lead.
- Patients with serum lead levels of 70 mcg/dL or more or those with lead encephalopathy should also be treated with dimercaprol (BAL). Administer these medications at separate sites.
- Intramuscular: IM is the preferred route for children and patients with lead encephalopathy. Lidocaine or procaine 1% should be added to minimize pain at injection site (1 mL procaine or lidocaine to 1 mL edetate calcium disodium ratio, for a final concentration of 0.5% procaine or lidocaine). Administer deep IM into well-developed muscle; massage well. Rotate sites.
Intravenous Administration
- Continuous Infusion: Diluent: Dilute in 250–500 mL D5W or 0.9% NaCl. Administer daily dose over 8–12 hr.
- Y-Site Compatibility: epinephrine
- Additive Incompatibility: D10W, LR
Patient/Family Teaching
- Home Care Issues: Discuss need for follow-up appointments to monitor lead levels. Additional treatments may be necessary.
- Consult public health department regarding potential sources of lead poisoning in the home, workplace, and recreational areas.
Evaluation/Desired Outcomes
- Decrease in symptoms of lead poisoning.
- Decrease in serum lead levels to below 20 mcg/dL, although the normal upper limit is 10 mcg/dL.